Merck’s remigromig meets non-inferiority goal in DME trial

Merck's DME treatment Remigromig achieved its non-inferiority endpoint in clinical trials, showing positive results.

AI CATALYST SCORE65 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

ANALYSIS HISTORY

MRK Analysis History (Last 30 Days)

Diagnosed At	Ticker	AI Score	Tier
2026-10-11 16:45:25	MRK	55	Mid	View Report →
2026-10-10 22:48:32	MRK	65	Mid	View Report →
2026-10-08 11:52:13	MRK	40	Row	View Report →

RELATED REPORTS

Diagnosed At	Ticker	AI Score	Tier
2026-10-12 21:24:50	JNJ	75	Mid	View Report →
2026-10-12 20:48:51	CSTL	50	Mid	View Report →
2026-10-12 17:35:30	JNJ	35	Row	View Report →
2026-10-12 17:03:53	AZN	45	Mid	View Report →
2026-10-12 16:17:22	REGN	65	Mid	View Report →
2026-10-12 16:17:01	JNJ	40	Row	View Report →
2026-10-12 15:42:29	ANIP	65	Mid	View Report →
2026-10-12 14:27:30	MIRM	85	Mid	View Report →
2026-10-12 13:27:32	MDT	87	S-Class	View Report →
2026-10-12 09:07:07	MMED	30	Row	View Report →
2026-10-12 07:54:04	PCRX	25	Row	View Report →
2026-10-12 04:45:25	ASTH	55	Mid	View Report →
2026-10-11 21:23:14	MIRM	35	Row	View Report →
2026-10-11 14:35:38	NEOG	30	Row	View Report →
2026-10-11 13:57:03	PCRX	35	Row	View Report →
2026-10-11 11:10:29	INSM	42	Row	View Report →
2026-10-11 10:37:58	LGND	40	Row	View Report →
2026-10-11 03:12:19	CSTL	40	Row	View Report →
2026-10-10 20:28:33	NEOG	35	Row	View Report →
2026-10-10 19:40:27	PCRX	25	Row	View Report →
2026-10-10 19:19:52	OPCH	30	Row	View Report →
2026-10-10 00:00:49	NEOG	20	Row	View Report →
2026-10-09 21:03:55	MRNA	78	S-Class	View Report →
2026-10-09 20:40:50	CCEL	82	S-Class	View Report →
2026-10-09 20:22:34	PRGO	60	Mid	View Report →
2026-10-09 19:27:23	ICLR	76	Mid	View Report →
2026-10-09 18:42:57	GSK	65	Mid	View Report →
2026-10-09 16:18:56	GKOS	72	Mid	View Report →
2026-10-09 16:00:36	JNJ	62	Mid	View Report →
2026-10-09 15:28:24	TEVA	75	S-Class	View Report →